BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37737263)

  • 1. Preexisting immunity restricts mucosal antibody recognition of SARS-CoV-2 and Fc profiles during breakthrough infections.
    Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang LF; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW
    JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37737263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal antibody responses following Vaxzevria vaccination.
    Selva KJ; Ramanathan P; Haycroft ER; Tan CW; Wang LF; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW
    Immunol Cell Biol; 2023; 101(10):975-983. PubMed ID: 37670482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
    Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
    Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
    Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
    Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern.
    Ruhl L; Kühne JF; Beushausen K; Keil J; Christoph S; Sauer J; Falk CS
    Front Immunol; 2023; 14():1120010. PubMed ID: 37033958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022.
    Cheng SM; Mok CKP; Chan KC; Ng SS; Lam BH; Luk LL; Ko FW; Chen C; Yiu K; Li JK; Chan KK; Tsang LC; Poon LL; Hui DS; Peiris M
    Euro Surveill; 2022 May; 27(18):. PubMed ID: 35514306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
    Liew F; Talwar S; Cross A; Willett BJ; Scott S; Logan N; Siggins MK; Swieboda D; Sidhu JK; Efstathiou C; Moore SC; Davis C; Mohamed N; Nunag J; King C; Thompson AAR; Rowland-Jones SL; Docherty AB; Chalmers JD; Ho LP; Horsley A; Raman B; Poinasamy K; Marks M; Kon OM; Howard L; Wootton DG; Dunachie S; Quint JK; Evans RA; Wain LV; Fontanella S; de Silva TI; Ho A; Harrison E; Baillie JK; Semple MG; Brightling C; Thwaites RS; Turtle L; Openshaw PJM; ;
    EBioMedicine; 2023 Jan; 87():104402. PubMed ID: 36543718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.
    Zhang H; Jiang Y; Tan H; Zou L; Zheng Z; Huang Y; Lin S; Su L; Yu J; Deng X; He J; Liu C; Shen C; Li B
    Virol J; 2022 Nov; 19(1):197. PubMed ID: 36434614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses.
    Puhach O; Bellon M; Adea K; Bekliz M; Hosszu-Fellous K; Sattonnet P; Hulo N; Kaiser L; Eckerle I; Meyer B
    EBioMedicine; 2023 Dec; 98():104893. PubMed ID: 38035462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva.
    Winklmeier S; Rübsamen H; Özdemir C; Wratil PR; Lupoli G; Stern M; Schneider C; Eisenhut K; Ho S; Wong HK; Taskin D; Petry M; Weigand M; Eichhorn P; Foesel BU; Mader S; Keppler OT; Kümpfel T; Meinl E
    Front Immunol; 2024; 15():1330864. PubMed ID: 38375482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of SARS-CoV-2 lineages and associated saliva antibody responses among asymptomatic individuals in a large university community.
    Merling MR; Williams A; Mahfooz NS; Ruane-Foster M; Smith J; Jahnes J; Ayers LW; Bazan JA; Norris A; Norris Turner A; Oglesbee M; Faith SA; Quam MB; Robinson RT
    PLoS Pathog; 2023 Aug; 19(8):e1011596. PubMed ID: 37603565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections.
    Saade C; Brengel-Pesce K; Gaymard A; Trabaud MA; Destras G; Oriol G; Cheynet V; Debombourg M; Mokdad B; Billaud G; Oblette A; Créhalet H; Giannoli JM; Garrigou C; Generenaz L; Compagnon C; Boibieux A; Lina B; Morfin F; Pozzetto B; Josset L; Trouillet-Assant S; Bal A
    Emerg Microbes Infect; 2022 Dec; 11(1):2423-2432. PubMed ID: 36098494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
    Pušnik J; Monzon-Posadas WO; Zorn J; Peters K; Baum M; Proksch H; Schlüter CB; Alter G; Menting T; Streeck H
    Nat Commun; 2023 Feb; 14(1):572. PubMed ID: 36732523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity.
    Nantel S; Sheikh-Mohamed S; Chao GYC; Kurtesi A; Hu Q; Wood H; Colwill K; Li Z; Liu Y; Seifried L; Bourdin B; McGeer A; Hardy WR; Rojas OL; Al-Aubodah TA; Liu Z; Ostrowski MA; Brockman MA; Piccirillo CA; Quach C; Rini JM; Gingras AC; Decaluwe H; Gommerman JL
    Mucosal Immunol; 2024 Apr; 17(2):201-210. PubMed ID: 38278415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees.
    Yu P; Liu Z; Zhu Z; Yang J; Deng M; Chen M; Lai C; Kong W; Xiong S; Wan L; Mai W; Chen L; Lei Y; Khan SA; Ruan J; Kang A; Guo X; Zhou Q; Li W; Chen Z; Liang Y; Li P; Zhang L; Ji T
    Virol Sin; 2023 Apr; 38(2):233-243. PubMed ID: 36603767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.